Categories: News
      Date: Feb  9, 2009
     Title: Examining the future of molecular imaging 

The future of molecular imaging and its impact on patient care highlighted the CPDC's inaugural probe development workshop on January 30.

More than 120 participants, spanning multiple sectors - academia, health care, not-for-profit, federal/provincial government and industry - gathered at the University Club on McMaster University's campus in Hamilton, Ontario. Workshop attendees learned about the latest innovations in molecular imaging and associated technologies from leaders in the field.

Featured speakers included:

• Jason S. Lewis, PhD, chief of Radiochemistry and associate vice chair of Basic Research at Memorial Hospital for Cancer and Allied Diseases, as well as an associate member within Memorial Sloan-Kettering Cancer Center.
• John Joyal, PhD, vice president of Discovery Research at Molecular Insight Pharmaceuticals in Cambridge, MA
• Brian Warrington, PhD, former vice president of Technology Development at GlaxoSmithKline in the United Kingdom
• Raymond Gibson, PhD, former senior investigator at Merck Research Laboratories in Philadelphia, PA

{cms_selflink page="john-valliant" text="CPDC Scientific Director and CEO John Valliant"} presented an overview of the Centre and the scope of services provided. He also opened the CPDC's inaugural Call for Proposals where applicants from Canadian not-for-profit research institutions with expertise in molecular probe development are eligible for project awards. {cms_selflink page="call-for-proposals" text="More details of the Call for Proposals »"}